Teva Launches Generic Version of Pfizer's Detrusitol; Geron Discontinues Phase II Study of Imetelstat Print E-mail
By Staff and Wire Reports   
Monday, 10 September 2012 19:00
Below is a look at some of the headlines for companies that made news in the healthcare sector on September 10, 2012.

Teva Pharmaceutical Industries (NYSE:TEVA)
announces the launch of generic Tolterodine 1mg and 2mg film-coated tablets, and Tolterodine XL (Mariosea XL) 4mg capsules.

Tolterodine is a generic version of Detrusitol ^® (tolterodine) from Pfizer Inc.(NYSE:PFE).  Tolterodine XL (Mariosea XL) is a generic version of Detrusitol ^® XL (tolterodine XL) from Pfizer.  Both are indicated in the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.  Please see the Summaries of Product Characteristics for more in-depth information.

Tolterodine and Tolterodine XL (Mariosea XL) are available immediately in the award-winning Teva 360 livery.

Kim Innes, Commercial Director at Teva said: "With the launch of tolterodine in all strengths and formulations, we're making more medicines accessible for more people. We've now launched twenty-four new products in 2012, and the launch of tolterodine is our twelfth patent expiry of the year so far. It adds to Teva's portfolio of medicines, which is already the UK's widest."


=====


Geron Corporation (Nasdaq: GERN)
announced, on the basis of an unplanned interim analysis, it is discontinuing its randomized Phase 2 study of imetelstat in metastatic HER2-negative breast cancer because median progression-free survival (PFS) in the imetelstat arm was shorter than in the comparator arm. The Company also announced that it is continuing its randomized Phase 2 study of imetelstat in advanced non-small cell lung cancer (NSCLC). However, although a separate interim analysis of the NSCLC study suggested a modest trend of efficacy in favor of the imetelstat arm, the pre-specified success criteria in this trial are unlikely to be met, and, as a consequence, it is doubtful that Geron will take imetelstat forward into Phase 3 development for NSCLC.  

The study in metastatic HER2-negative breast cancer was a randomized, controlled trial of 166 patients in which imetelstat was evaluated in combination with paclitaxel, compared to paclitaxel alone. The primary efficacy endpoint was an estimate of PFS.



Also Monday:



22nd Century Group, Inc. (OTCBB: XXII)
, a company that has developed groundbreaking technology for tobacco harm reduction and smoking cessation products, announced that Dr. Michael Moynihan, Vice President of Research & Development, will present a poster today on the company’s proprietary BRAND B cigarette at the 66th Tobacco Science Research Conference (TSRC) being held in Concord, North Carolina.

AmpliPhi Biosciences Corporation (APHB.PK)
(“Ampliphi”), today announced that it has offered to acquire Brookvale, Sydney-based Special Phage Services (“SPS”).

A.P. Pharma, Inc. (OTCBB: APPA)
today announced the appointment of Thomas Pitler, Ph.D. as vice president of business development.

Biogen Idec (NASDAQ: BIIB)
and DRI Capital today announced that Biogen Idec has sold to a DRI Capital managed fund (DRI) its royalty and other rights relating to BENLYSTA® (belimumab) to which Biogen Idec is entitled pursuant to a license agreement with Human Genome Sciences, Inc. and Glaxo Group Limited (both are companies within the GlaxoSmithKline group).

BioLineRx (NASDAQ: BLRX) (TASE: BLRX)
, a biopharmaceutical development company, announced today that BL-7010, an orally available treatment for celiac disease, was found to be safe and well tolerated in pre-clinical studies conducted to date.

Cellceutix Corporation (OTCBB: CTIX)
(the "Company"), a clinical stage biopharmaceutical company focused on discovering small molecule drugs for hard to treat diseases, is pleased to announce that it is in discussions with a major university (the "University") in Europe wishing to conduct clinical trials on Kevetrin™, the Company's flagship anti-cancer compound.

China Green Agriculture, Inc. (NYSE: CGA)
, a company that mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its wholly-owned subsidiaries in China, today announced that it will host a conference call to discuss the fiscal year 2012 financial results at 8:00 a.m. ET on Thursday, September 13, 2012.

Compugen Ltd. (NASDAQ: CGEN)
announced today that pre-clinical findings presented at the 3rd European Congress of Immunology provide additional support for the potential of CGEN-15001 to effectively treat autoimmune disease.

CompuMed, Inc. (OTCBB: CMPD)
(www.compumed.net) -- a leader in telemedicine services for patient diagnosis and management -- today announced that it has signed statewide contracts in conjunction with Wexford Health Sources, Inc.

CTPartners (NYSE MKT: CTP)
, a leading global retained executive search firm, announced today that Morten Nielsen has been appointed Managing Partner and Global Head of the Life Sciences & Healthcare practice.

DaVita Inc. (NYSE: DVA)
, a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), today announced that its new guest services contact center located in Centennial, Colo., is now open and has begun to serve patients from across the country.

Durata Therapeutics (NASDAQ:DRTX)
today announced cost-analysis data from a study investigating outpatient-based therapy for acute bacterial skin and soft tissue infections (abSSTI, a term synonymous with the more commonly used acute bacterial skin and skin structure infections, or ABSSSI).

Hydromer, Inc. (OTCQB: HYDI) (PINKSHEETS: HYDI)
announced that during August of its first fiscal quarter, it had entered into two royalty bearing License Agreements, one with a US-based medical device company, and one with a China-based medical device company.

Illumina, Inc. (NASDAQ:ILMN)
today announced it has appointed Paul Bianchi as Senior Vice President of Human Resources. In this executive management position, Bianchi will oversee Illumina’s global HR strategy and programs including talent and leadership development, employee engagement and communications, and rewards and recognition.

Islet Sciences, Inc., (OTCBB: ISLT)
a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital.

Mauna Kea Technologies (NYSE Euronext: MKEA)
, leader in the endomicroscopy market and developer of Cellvizio® imaging, the fastest way to see cancer, today announced the launch of the first dual color endomicroscopy imaging system, the Cellvizio® Dual Band.

Merck (NYSE: MRK)
, known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia.

NanoViricides, Inc. (OTC BB: NNVC)
(the "Company") announced today that oral administration of its FluCide™ anti-influenza drug candidates provided clinically important disease protection in a lethal animal model of influenza infection.

Nordion Inc. (TSX: NDN) (NYSE: NDZ)
announced today that it has received the decision in the confidential arbitration with Atomic Energy of Canada Limited (AECL).

Neuralstem, Inc. (NYSE MKT: CUR)
announced that President and CEO Richard Garr will present at the 2012 Rodman & Renshaw Annual Healthcare Conference on Tuesday, September 11 at 2:00 p.m. EDT, at The Waldorf=Astoria, Starlight South.

Oragenics, Inc. (OTCQB: ORNI)
(the “Company”) a world leader in oral health probiotics and systemic antibiotics, announced today that John N. Bonfiglio, President and CEO of Oragenics, will be presenting an update of the Company at the Rodman and Renshaw Annual Global Investment Conference September 9-11th, 2012.

Palatin Technologies, Inc. (NYSE MKT: PTN)
today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).

Parametric Sound Corporation (NASDAQ: PAMT)
, a leading innovator of audio products and solutions, today announced that it has appointed Fujitsu Frontech North America Inc., a leader in innovative technology and front-end solutions, to act as a non-exclusive, authorized reseller for the Company's HyperSound products.

Rocky Brands, Inc. (NASDAQ: RCKY)
has added two collections expanding the company's footprint into the outdoor adventure market and creating a new footwear option for healthcare professionals.

Sangamo BioSciences, Inc. (Nasdaq: SGMO)
announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for  HIV/AIDS, were presented at the 52ndInterscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

Senesco Technologies, Inc. (NYSE MKT: SNT)
announced today that the combination of bortezomib (the active component of VELCADE® marketed by Millennium, The Takeda Oncology Company) and SNS01-T, the subject of Senesco’s on-going multiple myeloma clinical study, performs significantly better than either treatment alone in mouse xenograft models.

Verisante Technology, Inc. (TSX VENTURE:VRS) (OTCQX:VRSEF) (FRANKFURT:V3T)
(the "Company" or "Verisante"), a leader in cancer detection technology, announced today that Thomas Braun, the Company's President and CEO will present at the Rodman & Renshaw 14th Annual Global Investment Conference which is being held at the Waldorf Astoria in New York, NY from September 9-11, 2012.

Zalicus Inc. (NASDAQ: ZLCS)
, a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive® in rheumatoid arthritis (RA).



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter